Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics. 2014;8:129–39.
2. Jasmin S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biol Targ Ther. 2014;8:281–91.
3. Alonso-Gordoa T, Diez JJ, Duran M, et al. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(1):22–38.
4. Eisai Inc. Lenvima (lenvatinib) capsules, for oral use: US prescribing information. 2015. http://www.fda.gov . Accessed 24 February 2015.
5. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–71.
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献